Axonics, Inc. announced the first patient implants in Canada with the Axonics F15™, the company's newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system. The University of Alberta implanted four patients this week with the Axonics F15. The four patients were programmed at stimulation amplitudes between 0.95mA and 0.30mA, resulting in an expected battery longevity in the body ranging from 18 years to over 22 years.

The Axonics F15 received regulatory approval from Health Canada following U.S. FDA approval. The comprehensive U.S. commercial launch of the Axonics F15 commenced in the second quarter of 2022.